enVVeno Medical Corporation presented one-year follow-up data from the VenoValve U.S. pivotal trial at the 37th Annual Meeting of the American Venous Forum, highlighting its impact on patients' quality of life (QoL). The data demonstrated sustained improvements across various venous-specific quality-of-life indicators.
This presentation further supports the VenoValve's comprehensive benefits for patients suffering from severe Chronic Venous Insufficiency, beyond just clinical scores. Improved quality of life is a significant factor for patient adoption and physician recommendation.
The company's Premarket Approval (PMA) application for the VenoValve was submitted in November 2024, with an FDA decision anticipated in the second half of 2025, maintaining the regulatory timeline for potential market entry.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.